$PLSE

PULSE BIOSCIENCES, INC. (PLSE): Submission of Matters to a Vote of Security Holders

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. plse20260607c_8k.htm false 0001625101 0001625101 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Rep

Original reporting
Published Jun 12, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$PLSE
Neutral
high confidence
Mentioned
$PLSE
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PLSENeutralLow
01

Why it matters

The disclosure confirms directors were elected and Deloitte & Touche was ratified as independent auditor for fiscal year ending Dec. 31, 2026; it does not introduce new financial guidance or business developments.

02

Market read

Primarily administrative governance information; unlikely to drive meaningful repricing absent additional catalysts.

03

What to watch

If there were contested director seats or auditor disputes, that could matter; however, the results shown indicate routine election/ratification with no stated controversy.

Relevance 6/10Novelty 2/10Timing: Filed June 12, 2026 for the June 11, 2026 annual meeting vote results.

Background

The company submitted voting matters from its 2026 annual stockholders meeting via SEC Form 8-K (Item 5.07).

Company-level read

Ticker impact

$PLSENeutralHigh confidence
Context

Pulse Biosciences filed an 8-K reporting the June 11, 2026 annual meeting vote results, including director elections and auditor ratification.

Expected impact

Low near-term impact; any reaction is likely limited to governance/administrative noise rather than fundamentals.

Evidence & confidence

The filing only documents votes (elect directors; ratify Deloitte & Touche) and provides no guidance, clinical, financing, or regulatory developments.

Market effects

Minimal; governance vote outcomes do not change biotech sector risk or read-across.

Minimal; no regional macro or cross-listed event described.

Minimal; no international transaction or regulatory action mentioned.

Counterpoint

Traders could treat auditor ratification as a minor diligence signal, but the filing lacks any change in auditor, scope, or accounting issues.

Key entities

  • Pulse Biosciences, Inc.

    Registrant; reported annual meeting voting outcomes on SEC Form 8-K.

  • Deloitte & Touche LLP

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

Related articles

$PLSEMedAI 8/10

Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) reported Q2 2026 revenue of $434,000 and GAAP net loss of $24.7 million. Cash and equivalents rose to $101.6 million by June 30, 2026 after $57.5 million in ATM proceeds. NANOPULSE-AF enrollment exceeded halfway with early October completion target; CE Mark for the catheter expected in 2H 2026.

$PLSEMed

PULSE BIOSCIENCES, INC. (PLSE): Results of Operations and Financial Condition

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results HAYWARD, California [Business Wire] — August 6, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-P

$WDSMed

Woodside Drops Its Climate Target and Leans Harder on Senegal

Woodside Energy abandoned its long-term Scope 3 climate targets, including a US$5 billion clean-energy investment plan. The company reported a 7% rise in underlying net profit to US$1.33 billion and a 27% increase in statutory net profit to US$1.67 billion. Woodside's Senegalese field, Sangomar, is central to its strategy, with production averaging 99,000 barrels per day. The company is also in a tax arbitration with Senegal's government over a US$68 million reassessment.

MedAI 8/10

Electrovaya CEO: Amazon deal is ‘validation’

Electrovaya and Amazon expanded their commercial agreement, with Amazon receiving warrants for up to 13.9 million Electrovaya shares upon achieving $280 million in purchases. The deal includes potential applications in robotics and energy storage. Electrovaya's CEO views this as strong validation of their technology. Additionally, Electrovaya's partnership with Sumitomo is driving growth in the Asia-Pacific region, with material deliveries expected from fiscal 2027.

$TRGPMedAI 8/10

Finding profits in oil and gas pipelines

Targa Resources (TRGP) shares rose 10% after a 20-year deal with ExxonMobil to build energy infrastructure. The company plans new processing plants and pipelines, increasing capital spending to $5B. Midstream firms like Targa are vital for transporting oil and gas, with global pipeline investments growing.